IMMUNOSCORE® IC in Non-Small Cell Lung cancer Toward an improved prediction of response to ICIs

Why IMMUNOSCORE® IC?

IMMUNOSCORE® IC is intended for the detection of PD-L1 protein and the concomitant detection of CD8 + cells in Non-Small Cell Lung cancer (NSCLC) tissue.

IMMUNOSCORE® IC, as a member of the IMMUNOSCORE® family assays, is a standardized Immunohistochemistry (IHC)-based assay.

In addition, HalioDx provides image and data analysis services allowing standardized quantification of both PD-L1+ and CD8+ cell populations and the assessment of cells clustering as well as a proximity index. These measures aim to help identifying which NSCLC patients may best respond to anti-PD1 or anti-PD-L1 immunotherapies.

IMMUNOSCORE® IC is available as a CE-IVD assay for PD-L1+ cells detection and as an RUO* solution in the Rest of The World through our comprehensive offer integrating HalioDx service laboratory.

 

* For Research Use Only. Not for use in diagnostic procedures.

IMMUNOSCORE® IC
Indication: NSCLC
Material: One FFPE slide
Assay: PD-L1+ & CD8+ cells detection by immunohistochemistry
Digital pathology: computation of CD8+ & PD-L1+ cell densities
Score & report: clustering of CD8+ & PD-L1+ cells
and CD8+ & PD-L1+ proximity index

IMMUNOSCORE® IC solution consists in two parts:

  1. IMMUNOSCORE® IC IHC kit includes ready-to-use anti-PD-L1 and anti-CD8 antibodies and controls for IHC dual-staining. The stained slide is directly readable by the pathologist to determine the percentage of PD-L1 positive tumor cells, evaluate the presence of PDL1+ immune cells and of CD8+ cells.
  2. Image analysis for complementary descriptive information:
  • Standardized computation of CD8+ and PD-L1+ cell densities on the same slide
  • PD-L1+ and CD8+ cells clustering
  • Proximity index between PD-L1+ and CD8+ cells

 

Clinical utility

IMMUNOSCORE® IC is intended to help clinicians defining immunotherapy treatment strategy for patients with NSCLC.

Anti-PD-1/PD-L1 are now established treatments for advanced NSCLC patients; however, PD-L1 predictive value is not optimal. Association of PD-L1 + TC % with the assessment of tumor-infiltrating lymphocytes (TILs) via CD8+ T cells quantification and proximity measurement should improve the selection of patients likely to respond to Immune Checkpoint Inhibitors treatment.

See IMMUNOSCORE® IC (previously Halioseek® PD-L1/CD8) Digital Pathology Tool Performance (SITC 2017)


IMMUNOSCORE® IC workflow

How to Order

Depending on your laboratory equipment IMMUNOSCORE® IC is available as a CE-IVD test (Europe only) for PD-L1 assessment directly in your laboratory or in a full service process (performed in HalioDx laboratories) through a standardized and validated workflow. For image analysis services and to access to IMMUNOSCORE® IC documentation, please contact HalioDx.

See our General Terms and Conditions

 


Want to learn more on IMMUNOSCORE® IC in Non-Small Cell Lung cancer ? Contact us

 

 

Posters on IMMUNOSCORE® IC in NSCLC


#Immunoscore® Lung
Poster

#poster | avril. 2018

Poster presented at AACR 2018

Multi-centric PD-L1 and CD8 IHC assessment in NSCLC using IMMUNOSCORE® IC previously Halioseek®) CE-IVD assay

#Immunoscore® Lung
Poster

#poster | nov.. 2017

Poster presented at SITC 2017

Immunoscore IC (previously Halioseek® PD‐L1/CD8), a dual CD8 and PD‐L1 IVD assay to improve NSCLC patients stratification

#Immunoscore® Lung
Poster

#poster | avril. 2017

Poster presented at AACR 2017

A new standardized CD8 and PD-L1 dual assay


Selected publications


See all resources available Resources